preferred drug
Scope
Date
~
-
Bio & Pharma
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
JVM to sell fully automated drug inspection machines in US
Hanmi Pharmaceutical Co. said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug d...
Jan 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Chemical Industry
Solvay named preferred bidder to buy Solus Biotech
Belgian chemicals maker Solvay S.A. has been selected as the preferred bidder to acquire South Korean biomaterials maker Solus Biotech, according to...
Dec 29, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma, Neurolive to jointly develop new antidepressant drug
South Korea's drug company Daewoong Pharmaceutical said on Wednesday that it has signed an agreement with biopharmaceutical venture Neurorive to joi...
Dec 28, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Dong-A ST incorporates NeuroBo as subsidiary
Dong-A ST said on Friday that it would acquire American drug company NeuroBo Pharmaceuticals as a subsidiary.NeuroBo, located in Boston, is a Nasdaq...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biopharmaceutical sector to see brisk M&As in H1, 2023
An expert says the first half of next year will see the start of brisk M&As in biopharmaceuticals targeting strategic investors.Pyeon Jae-seong,...
Dec 21, 2022 (Gmt+09:00)
-
Artificial intelligence
Syntekabio launches new drug development platform STB Cloud in US
Syntekabio,Inc., a South Korean artificial intelligence (AI) drug development company, said on Monday it has launched its cloud-based AI drug develo...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)
-
Bio & Pharma
Daewoong submits new drug applications for Fexuclue in 10 countries
South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fex...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug
South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swis...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials
LG Chem Ltd. announced in a disclosure on Monday that it had confirmed superior efficacy in phase 3 clinical trials for the combined administration ...
Dec 13, 2022 (Gmt+09:00)
-
Bio & Pharma
New drug developer Onconic Therapeutics raises $20 mn in Series B
South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
Korea approves Daewoong Pharmaceutical's diabetes drug
DAEWOONG PHARMACEUTICAL has received domestic approval for its diabetes drug Envlo with the active ingredient enavogliflozin, the second straight ye...
Dec 02, 2022 (Gmt+09:00)
-
Mergers & Acquisitions
MBK to buy Medit at lower price than Carlyle-GS bid
MBK Partners, a leading Asian private equity firm, is set to buy Medit Corp. at a lower price than a bid from the US PE giant The Carlyle Group-led ...
Nov 29, 2022 (Gmt+09:00)
-
Travel & Leisure
Seoul reclaims spot as Japanese tourists' top destination after 11 yrs: HIS
Seoul has become the top destination for Japanese tourists for the first time since 2011, according to Japan’s leading travel agency HIS Gro...
Nov 28, 2022 (Gmt+09:00)
-
Bio & Pharma
Spectrum to push back launch date of Hanmi-developed drug Poziotinib
Hanmi Pharmaceutical Co. announced Friday that California-based Spectrum Pharmaceuticals Inc. received a Complete Response Letter (CRL) from the US ...
Nov 25, 2022 (Gmt+09:00)
-
Real estate
Nexon named preferred bidder for 50% of office tower from KTCU
Gaming giant Nexon Co. is set to acquire a 50% stake in the Autoway Tower, an office building in Seoul's Gangnam business district, from the Korean ...
Nov 25, 2022 (Gmt+09:00)
-
Bio & Pharma
Mezzion Pharma to try again for US FDA approval of drug
South Korea's Mezzion Pharma will seek to get the oral medicine Udenafil to treat side effects from heart surgery, planning to clinical trials in th...
Nov 23, 2022 (Gmt+09:00)
-
Mergers & Acquisitions
Sale of Korean dental scanner maker Medit fails
The sale of South Korea's dental scanner manufacturer Medit will undergo a reset as the preferred bidder, a consortium led by GS Holdings and the US...
Nov 14, 2022 (Gmt+09:00)
-
Bio & Pharma
No more ineffective drugs due to resistance
L-Base is a pharmaceutical startup specializing in developing drugs for those who become resistant to existing cancer treatments. This year, the Minis...
Nov 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Moderna to stay ahead in mRNA technology: CSO Melissa Moore
CAMBRIDGE, MA – The COVID-19 coronavirus disease has been a curse for many people and companies around the world over the past couple of years...
Oct 14, 2022 (Gmt+09:00)
-
Bio & Pharma
SillaJen shares jump as exchange maintains listing, allows resumed trade
Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the...
Oct 13, 2022 (Gmt+09:00)
-
Corporate bonds
Korean corporate bond issuance hits 2022 monthly low in September
South Korean corporate bond issuance in September hit a monthly low this year on souring investor sentiment due to interest rate hikes.Corporate bon...
Oct 07, 2022 (Gmt+09:00)